PIK3CA and breast carcinoma: Given that the PI3K pathway alterations have a high impact in patients with ER+/HER2+ breast cancer (Fig. 1), we first evaluated cell viability using ER+/HER2+ breast cancer cell lines with or without PIK3CA mutations.